Objective:To study the effects of dexzopiclone and estazolam on neurotransmitters, nerve cytokines and stress states in patients with insomnia after stroke.Methods: The patients with insomnia after stroke who were tre...Objective:To study the effects of dexzopiclone and estazolam on neurotransmitters, nerve cytokines and stress states in patients with insomnia after stroke.Methods: The patients with insomnia after stroke who were treated in Linyi Rongjun Hospital between March 2015 and October 2017 were chosen and randomly divided into dexzopiclone group and estazolam group. The levels of neurotransmitters, nerve cytokines and stress indexes in serum were measured before treatment as well as 14 days and 28 days after treatment.Results: Compared with those before treatment, serum Glu,γ-GABA, 5-HT, 5-HIAA, BDNF and NGF levels of both groups significantly increased whereas NE, TNF-α, IL-6, ATCH, Cor, CRP, SOD and GSH levels significantly decreased after treatment, and serum Glu,γ-GABA, 5-HT, 5-HIAA, BDNF and NGF levels of dexzopiclone group after treatment were higher than those of estazolam group whereas NE, TNF-α, IL-6, ATCH, Cor, CRP, SOD and GSH levels were lower than those of estazolam group.Conclusion:Dexzopiclone is more effective than estazolam to regulate the secretion of neurotransmitters and nerve cytokines and reduce the stress state in patients with insomnia after stroke.展开更多
As one of common physical and mental ailments, insomnia may cause serious adverse effects on a patient＇s daily life. And serious accidents occur in long-term cases.1 Despite comprehensive treatments, 9.38%-17.0% of...As one of common physical and mental ailments, insomnia may cause serious adverse effects on a patient＇s daily life. And serious accidents occur in long-term cases.1 Despite comprehensive treatments, 9.38%-17.0% of the treated insomniacs fail to benefit at all. Thus the term of ＂refractory insomnia＂ has been coined.24 At present, there is no literature reporting the roles of estazolam plus alternating current magnetic field （ACMF） for treating insomnia. In the present study, estazolam plus ACMF was employed for the patients with refractory insomnia so as to explore the clinical efficacies of such a combined modality.展开更多
文摘Objective:To study the effects of dexzopiclone and estazolam on neurotransmitters, nerve cytokines and stress states in patients with insomnia after stroke.Methods: The patients with insomnia after stroke who were treated in Linyi Rongjun Hospital between March 2015 and October 2017 were chosen and randomly divided into dexzopiclone group and estazolam group. The levels of neurotransmitters, nerve cytokines and stress indexes in serum were measured before treatment as well as 14 days and 28 days after treatment.Results: Compared with those before treatment, serum Glu,γ-GABA, 5-HT, 5-HIAA, BDNF and NGF levels of both groups significantly increased whereas NE, TNF-α, IL-6, ATCH, Cor, CRP, SOD and GSH levels significantly decreased after treatment, and serum Glu,γ-GABA, 5-HT, 5-HIAA, BDNF and NGF levels of dexzopiclone group after treatment were higher than those of estazolam group whereas NE, TNF-α, IL-6, ATCH, Cor, CRP, SOD and GSH levels were lower than those of estazolam group.Conclusion:Dexzopiclone is more effective than estazolam to regulate the secretion of neurotransmitters and nerve cytokines and reduce the stress state in patients with insomnia after stroke.
文摘As one of common physical and mental ailments, insomnia may cause serious adverse effects on a patient＇s daily life. And serious accidents occur in long-term cases.1 Despite comprehensive treatments, 9.38%-17.0% of the treated insomniacs fail to benefit at all. Thus the term of ＂refractory insomnia＂ has been coined.24 At present, there is no literature reporting the roles of estazolam plus alternating current magnetic field （ACMF） for treating insomnia. In the present study, estazolam plus ACMF was employed for the patients with refractory insomnia so as to explore the clinical efficacies of such a combined modality.
